Research progress in targeted therapy and immunotherapy for gastric cancer

被引：17

作者：

Li, Xuewei ^{[1
]}

Xu, Jun ^{[2
]}

Xie, Jun ^{[1
]}

Yang, Wenhui ^{[3
]}

机构：

[1] Shanxi Med Univ, Dept Biochem & Mol Biol, Shanxi Key Lab Birth Defect & Cell Regenerat, Taiyuan 030001, Shanxi, Peoples R China

[2] Shanxi Med Univ, Dept Surg, Hosp 1, Taiyuan 030001, Shanxi, Peoples R China

[3] Shanxi Med Univ, Shanxi Bethune Hosp, Shanxi Acad Med Sci, Canc Ctr,Hosp 3, Taiyuan 030032, Shanxi, Peoples R China

来源：

CHINESE MEDICAL JOURNAL | 2022年 / 135卷 / 11期

基金：

中国国家自然科学基金;

关键词：

Angiogenesis; Cytotoxic T lymphocyte-associated antigen-4; Epidermal growth factor receptor; Gastric cancer; Immunotherapy; Programed cell death ligand 1; Programed death-1; Targeted therapy; Vascular endothelial growth factor; GASTROESOPHAGEAL JUNCTION CANCER; PHASE-II TRIAL; DOUBLE-BLIND; PROGNOSTIC-SIGNIFICANCE; PLUS OXALIPLATIN; SOLID TUMORS; COMBINATION; BEVACIZUMAB; CHEMOTHERAPY; OVEREXPRESSION;

D O I：

10.1097/CM9.0000000000002185

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Gastric cancer (GC) is one of the most common malignant tumors worldwide. Its incidence ranks the 5th among all malignant tumors globally, and it is the 3rd leading cause of death among patients with cancer. Surgical treatment is the first choice in clinical practice. However, targeted therapy, immunotherapy, and other treatment methods have also become research hotspots at home and abroad with the development of individualized precision therapy in recent years, besides traditional radiotherapy and chemotherapy. At present, targeted therapy and immunotherapy are methods used for treating GC, and they have important clinical application value and prospects. This study aimed to review the research progress of targeted therapy and immunotherapy for GC, focusing on its mechanism of action and related important clinical trials, hoping to provide references for the clinical treatment of GC.

引用

页码：1299 / 1313

页数：15

共 93 条

[1] Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer [J].

Adashek, Jacob J. ;

Arroyo-Martinez, Yadis ;

Menta, Arjun K. ;

Kurzrock, Razelle ;

Kato, Shumei .

FRONTIERS IN ONCOLOGY, 2020, 10

[2] Gastric Cancer, Version 3.2016 [J].

Ajani, Jaffer A. ;

D'Amico, Thomas A. ;

Almhanna, Khaldoun ;

Bentrem, David J. ;

Chao, Joseph ;

Das, Prajnan ;

Denlinger, Crystal S. ;

Fanta, Paul ;

Farjah, Farhood ;

Fuchs, Charles S. ;

Gerdes, Hans ;

Gibson, Michael ;

Glasgow, Robert E. ;

Hayman, James A. ;

Hochwald, Steven ;

Hofstetter, Wayne L. ;

Ilson, David H. ;

Jaroszewski, Dawn ;

Johung, Kimberly L. ;

Keswani, Rajesh N. ;

Kleinberg, Lawrence R. ;

Korn, W. Michael ;

Leong, Stephen ;

Linn, Catherine ;

Lockhart, A. Craig ;

Ly, Quan P. ;

Mulcahy, Mary F. ;

Orringer, Mark B. ;

Perry, Kyle A. ;

Poultsides, George A. ;

Scott, Walter J. ;

Strong, Vivian E. ;

Washington, Mary Kay ;

Weksler, Benny ;

Willett, Christopher G. ;

Wright, Cameron D. ;

Zelman, Debra ;

McMillian, Nicole ;

Sundar, Hema .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (10) :1286-1312

[3] Novel therapeutic targets in non-small cell lung cancer [J].

Alamgeer, Muhammad ;

Ganju, Vinod ;

Watkins, D. Neil .

CURRENT OPINION IN PHARMACOLOGY, 2013, 13 (03) :394-401

[4] PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome [J].

Alsaab, Hashem O. ;

Sau, Samaresh ;

Alzhrani, Rami ;

Tatiparti, Katyayani ;

Bhise, Ketki ;

Kashaw, Sushil K. ;

Iyer, Arun K. .

FRONTIERS IN PHARMACOLOGY, 2017, 8

[5] HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women [J].

Aman, Nguiessan Alphonse ;

Doukoure, Brahima ;

Koffi, Kouadio Donatien ;

Koui, Baumaney Sylvanus ;

Traore, Zie Cheick ;

Kouyate, Mohamed ;

Effi, Ahoua Benjamin .

BMC CLINICAL PATHOLOGY, 2019, 19

[6] Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use [J].

Aprile, Giuseppe ;

Bonotto, Marta ;

Ongaro, Elena ;

Pozzo, Carmelo ;

Giuliani, Francesco .

DRUGS, 2013, 73 (18) :2003-2015

[7] Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer [J].

Azar, Ibrahim ;

Alkassis, Samer ;

Fukui, Jami ;

Alsawah, Fares ;

Fedak, Kalub ;

Al Hallak, Mohammed Najeeb ;

Sukari, Ammar ;

Nagasaka, Misako .

LUNG CANCER-TARGETS AND THERAPY, 2021, 12 :103-114

[8] Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 [J].

Bang, Y. -J. ;

Ruiz, E. Yanez ;

Van Cutsem, E. ;

Lee, K. -W. ;

Wyrwicz, L. ;

Schenker, M. ;

Alsina, M. ;

Ryu, M. -H. ;

Chung, H. -C. ;

Evesque, L. ;

Al-Batran, S. -E. ;

Park, S. H. ;

Lichinitser, M. ;

Boku, N. ;

Moehler, M. H. ;

Hong, J. ;

Xiong, H. ;

Hallwachs, R. ;

Conti, I. ;

Taieb, J. .

ANNALS OF ONCOLOGY, 2018, 29 (10) :2052-2060

[9]

Bang YJ, 2010, LANCET, V376, P1302

[10] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study [J].

Bang, Yung-Jue ;

Kang, Yoon-Koo ;

Catenacci, Daniel V. ;

Muro, Kei ;

Fuchs, Charles S. ;

Geva, Ravit ;

Hara, Hiroki ;

Golan, Talia ;

Garrido, Marcelo ;

Jalal, Shadia I. ;

Borg, Christophe ;

Doi, Toshihiko ;

Yoon, Harry H. ;

Savage, Mary J. ;

Wang, Jiangdian ;

Dalal, Rita P. ;

Shah, Sukrut ;

Wainberg, Zev A. ;

Chung, Hyun Cheol .

GASTRIC CANCER, 2019, 22 (04) :828-837

← 1 2 3 4 5 6 7 8 9 10 →